Ocular Therapeutix's Wet AMD Candidate Shows Sustained, Comparable Clinical Activity Vs. Eylea

  • Ocular Therapeutix Inc OCUL announced interim 7-month data from its U.S. Phase 1 trial evaluating OTX-TKI for wet age-related macular degeneration (wet AMD) and other retinal diseases. 
  • Interim data showed that the single OTX-TKI implant was generally well tolerated with a favorable safety profile. No drug-related ocular or systemic serious adverse events (SAEs) were observed. 
  • After the mandated aflibercept injection, one SAE of endophthalmitis was observed in the OTK-TKI arm. 
  • Single OTX-TKI implant demonstrated stable and sustained best corrected visual acuity (BCVA) and central subfield thickness (CSFT), comparable with Regeneron Pharmaceuticals Inc's REGN Eylea (aflibercept).
  • About 80% of subjects in the OTX-TKI arm were rescue-free for up to 6 months, and 73% of subjects in the OTX-TKI arm were rescue-free for up to 7 months. FDA has not reviewed these data.
  • The company plans to complete its analysis, meet with the FDA to discuss potential future clinical trial requirements, and initiate a Phase 2 wet AMD trial in Q3 of 2023. 
  • Ocular also plans to follow subjects in the Phase 1 trial at least until their respective one-year anniversaries of initial dosing under the clinical trial protocol. 
  • It also plans to initiate a U.S.-based Phase 1 clinical trial to evaluate OTX-TKI for diabetic retinopathy in Q1 of 2023.
  • Price Action: OCUL shares are down 7% at $4.91 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!